Protagonist Therapeutics coverage assumed with buy rating and $171 target price
PTGX•Jefferies assumed coverage of Protagonist Therapeutics with a buy rating and a $171 target price.
Related News

Clorox declares quarterly dividend of $1.25 per share
CLX•

Torex Resources presents plans to expand Morelos processing capacity by up to 35%
TXG•

Affirm publishes fiscal Q1 2027 earnings call transcript
AFRM•

Sallie Mae: RBC cuts target price to $21 from $26
SLM•

New York’s Fifth Avenue regains world’s priciest retail street ranking, Cushman & Wakefield says
XLRE•